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ABSTRACT
Background SDHB is one of the major genes 
predisposing to paraganglioma/pheochromocytoma 
(PPGL). Identifying pathogenic SDHB variants in patients 
with PPGL is essential to the management of patients 
and relatives due to the increased risk of recurrences, 
metastases and the emergence of non- PPGL tumours. 
In this context, the ’NGS and PPGL (NGSnPPGL) Study 
Group’ initiated an international effort to collect, 
annotate and classify SDHB variants and to provide 
an accurate, expert- curated and freely available SDHB 
variant database.
Methods A total of 223 distinct SDHB variants from 
737 patients were collected worldwide. Using multiple 
criteria, each variant was first classified according to a 
5- tier grouping based on American College of Medical 
Genetics and NGSnPPGL standardised recommendations 
and was then manually reviewed by a panel of experts in 
the field.
Results This multistep process resulted in 23 benign/
likely benign, 149 pathogenic/likely pathogenic variants 
and 51 variants of unknown significance (VUS). Expert 
curation reduced by half the number of variants initially 
classified as VUS. Variant classifications are publicly 
accessible via the Leiden Open Variation Database 
system (https:// databases. lovd. nl/ shared/ genes/ SDHB).
Conclusion This international initiative by a panel of 
experts allowed us to establish a consensus classification 
for 223 SDHB variants that should be used as a 
routine tool by geneticists in charge of PPGL laboratory 
diagnosis. This accurate classification of SDHB genetic 
variants will help to clarify the diagnosis of hereditary 
PPGL and to improve the clinical care of patients and 
relatives with PPGL.
INTRODUCTION
The SDHB protein (OMIM185470) corresponds 
to the catalytic iron- sulfur subunit of the heterote-
trameric succinate dehydrogenase (SDH) complex, 
a component of both the tricarboxylic acid cycle 
and the mitochondrial respiratory chain (complex 
II). Germline inactivating SDHB pathogenic vari-
ants were first identified in kindreds with familial 
pheochromocytoma and paraganglioma (PPGL).1 
Paragangliomas (PGL) and pheochromocytomas 
(PCC) are rare neuroendocrine tumours arising 
from the sympathetic/parasympathetic ganglia and 
the adrenal medulla, respectively. Among human 
tumours, PPGLs show the highest frequency of 
hereditary forms of the disease, representing at 
least 35% of all cases.2 For this reason, some PPGL 
guidelines recommend that genetic testing should 
be considered in all patients with PPGL.3 4 Over 20 
genes are known to increase susceptibility to PPGL. 
SDHB, which acts as a tumour suppressor gene, 
is one of the most frequently involved, consid-
ering that around 10% of all PPGL cases carry an 
SDHB- pathogenic variant, including patients with 
apparently sporadic disease.2 5–7 SDHB therefore is 
included in the primary (also referred to as ‘basic’) 
panel of genes routinely analysed in patients with 
PPGL, all of which were validated as bona fide 
susceptibility genes.2 4 SDHB pathogenic variants 
most commonly predispose to head and neck PGLs, 
sympathetic PGLs and PCCs, and also give rise to 
renal cell carcinomas (RCC), wild- type gastroin-
testinal stromal tumours (wtGIST) and pituitary 
adenomas.8 Moreover, SDHB pathogenic variants 
have been associated with a high risk of metastasis 
and a poor prognosis.9 10 As SDHB patients face a 
high risk of disease recurrence, possible emergence 
of non- PPGL tumours such as RCCs and wtGISTs 
and metastatic evolution, it is essential to patient 
management and follow- up that the identification 
of an SDHB variant is followed by an accurate classi-
fication as ‘disease causing’ or not. Determining the 
pathogenicity of an SDHB variant is also a precon-
dition for presymptomatic genetic testing of rela-
tives and the appropriate management of carriers 
of pathogenic variants. Indeed, the ‘unclassified 
genetic variants’ working group at the International 
Agency for Research on Cancer recommends that 
predictive genetic testing of at- risk relatives should 
be confined to pathogenic or likely pathogenic 
variants.11
Public gene- specific databases already exist for 
various PPGL susceptibility genes. The NGS in 
PPGL (NGSnPPGL) Study Group—which includes 
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18 experts from 8 countries and includes both clinicians and 
basic researchers involved in PPGL genetic testing and genetic 
counseling—published a consensus statement in 2017 empha-
sising the importance of multi- institutional, internationally 
shared efforts to compile resources for genomic, clinical and 
functional data, including the comprehensive annotation of vari-
ants and encouraging public sharing of novel variants.2
The SDHB variant database was created in 2005, using the 
Leiden Open Variation Database (LOVD) platform (https:// 
databases. lovd. nl/ shared/ genes/ SDHB).12 The database mainly 
consists of variants extracted from the published literature 
but increasingly includes directly submitted variants. As of 
September 2020, the LOVD- SDHB comprises 288 unique vari-
ants for which a detailed nomenclature, clinical and segregation 
data, as well as publication references are available.13
Here, we present an international initiative of the NGSnPPGL 
study group to provide a comprehensive annotation of SDHB 
variants, to gather variants identified in laboratories worldwide 
that perform SDHB molecular analysis and to collect extensive 
data associated with these variants including patient phenotype 
and in silico, functional or additional analyses performed in each 
case. Based on these data, each variant was classified according 
to both the American College of Medical Genetics and Genomics 
(ACMG) and the Association for Molecular Pathology criteria,14 
and the NGSnPPGL guidelines,2 into one of five classes of 
pathogenicity.11 All variants were then manually reviewed by a 
panel of international experts in the field, leading to a consensus 
classification. Our main goal was to provide a freely available, 
expert- curated, SDHB variant database, offering an accurate and 
harmonised interpretation that will improve the care of patients 
and families carrying these variants.
METHODS
Data collection
Data on patients carrying an SDHB variant were submitted by 
10 laboratories worldwide, which routinely perform the SDHB 
genotyping and belong to the European Network for the Study 
of Adrenal Tumors (ENS@T) and/or the Pheochromocytoma 
and paraganglioma RESearch Support Organization (PRESSOR) 
and/or the French Oncogenetics Network of Rare Neuroendo-
crine Tumors (TENgen network). Data on 737 index cases were 
collected, including 386 from France (5 laboratories located in 
Georges Pompidou European Hospital—Paris, La Conception 
hospital—Marseille, Hospices Civils—Lyon, Centre hospitalo- 
universitaire—Lille and Centre hospitalo- universitaire—
Angers), 215 from the UK (Cambridge/Birmingham), 71 from 
Spain (Madrid), 32 from the USA (San Antonio, Texas), 20 from 
Italy (Firenze) and 13 from Australia (Sydney). Patients carrying 
only well- known single nucleotide polymorphisms of SDHB 
gene were not enrolled.
Clinical data collected for each index case included the type, 
number and site of tumours; the age at diagnosis; the metastatic 
status (defined by the presence of metastases in non- paraganglial 
tissue15); the biochemical secretion profile and the family history 
of SDHB spectrum tumours. Co- segregation data in families 
were reported when available.
All data have been collected retrospectively and de- identified.
Molecular data
The nuclear SDHB gene (1p36) covers 8 exons and encodes a 
281 amino acid protein.
Genotyping of leucocyte DNA was performed locally 
and included the sequencing of the full coding regions and 
exon- intron junctions using the Sanger or the next- generation 
sequencing (NGS) methods together with search for large rear-
rangements using Multiplex Ligation- dependent Probe Amplifi-
cation (MLPA, MRC- Holland).
All variants were annotated according to the NM_003000.2 
reference transcript on genome assembly GRCh37 (hg19) and 
following Human Genome Variation Society nomenclature 
(https:// varnomen. hgvs. org/). For each variant, the DNA and 
protein changes were collected. Other tested genes and the 
co- occurrence of additional variants of interest were specified by 
submitters when pertinent.
Previous reports for each variant were checked in dbSNP, 
exome variant server, gnomAD and ClinVar databases through 
AlamutVisual software, V.2.10 (Interactive Biosoftware, Sophia 
Genetics) (online supplemental table 1). Variant frequencies in 
reference populations and literature references were included 
when available.
In silico predictions
For missense variants, in silico analyses were performed based 
on amino acid conservation among 14 orthologs and expressed 
as a ratio between 0 and 1 (x orthologs sharing the same amino 
acid/14), nucleotide conservation was based on PhyloP and 
Grantham distance score and predicted impact were derived 
from PolyPhen2 (HumVar), SIFT, Align- GVGD and Mutation 
Taster. Predicted impact according to MaxEntScan and NNSplice 
was estimated for variants with a potential splice effect (splic-
esite synonymous and intronic variants). The tools used and the 
corresponding thresholds are described in online supplemental 
table 1.
Additional data
Supporting information such as loss of heterozygosity (LOH) 
in tumour DNA, cDNA analysis, SDHB and/or SDHA immu-
nohistochemistry on FFPE tumour tissue sections, SDH enzy-
matic activity and other pertinent assays were reported when 
available (online supplemental table 2). Because SDHB func-
tions as a tumour suppressor gene with loss of the wild- type 
allele in tumour tissue, LOH analysis was performed when 
both germline and tumour samples were available. In case of 
variants possibly leading to abnormal splicing, cDNA analysis 
was performed when leucocyte or tumour RNA was available. 
SDHB immunohistochemistry and SDH enzymatic activity 
measurement are useful tools to discriminate SDHx- related and 
non-SDHx- related tumours, as a loss of SDHB protein or SDH 
activity reliably signals the presence of an SDHx deleterious 
variant in tumour cells.16 17 Negative SDHB immunostaining 
or loss of SDH activity, combined with negative SDHC, SDHD 
and SDHA (or positive SDHA immunohistochemistry18) geno-
typing, is a hallmark of SDHB loss- of- function variants. When 
available, tumour classification in cluster 1A (SDHx- related), 1B 
(VHL- related) or 2A (RET/NF1/sporadic tumours), according 
to previous transcriptomic analyses19 20 was specified, as well as 
SDHB protein expression as evaluated by western blot analysis 
(online supplemental figure 1).
Variant classifications
All variants were classified according to ACMG criteria14 
adjusted to SDHB gene and PPGL specificities (online supple-
mental figure 1). As they are not applicable and/or established 
for the SDHB gene, the following criteria were not considered: 
PS4 (prevalence in affected individuals statistically increased 
over controls); BP1 (missense in gene where only truncating 
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cause disease); PP2 (missense in gene with low rate of benign 
missense variants and pathogenic missenses common); PM1 
(mutational hot spot or well- studied functional domain without 
benign variation); PM3 (for recessive disorders, detected in 
trans with a pathogenic variant); PM6 and PS2 (because de novo 
cases are very rare, SDHB variants are usually inherited, even 
from unaffected parents due to low penetrance of the disease). 
As there are multiple PPGL susceptibility genes, PP4 criteria 
(patient’s phenotype or family history highly specific for gene) 
were not retained for classification. Additional data criteria were 
adapted as follows: benign strong (loss of the allele carrying the 
SDHB variant in tumour DNA), benign supporting (no LOH at 
the SDHB locus, assay not in favour of SDHB loss of function), 
pathogenic supporting (LOH at the SDHB locus), pathogenic 
moderate (assay in favour of SDH loss of function without all 
SDHx genes analysed), pathogenic strong (evidence for SDH loss 
of function and no additional variant found in SDHx genes), 
pathogenic very strong (evidence for SDHB- specific loss of func-
tion) (online supplemental figure 1). We also considered other 
criteria calibrated between benign strong and pathogenic strong 
according to number of published cases and previously reported 
evidence.
Variants were also classified according to the NGSnPPGL 
study group framework2 based on the frequency of the variant 
in the general population, the variant type, in silico predictions, 
co- segregation in families and the results of additional informa-
tion or assays available in the literature or for the submitted cases 
(online supplemental figure 2).
Both classifications assigned each variant to one of the 
following classes: benign variant (BV, class 1), likely benign 
variant (LBV, class 2), variant of unknown significance (VUS, 
class 3), likely pathogenic variant (LPV, class 4) or pathogenic 
variant (PV, class 5).
After data collection, in silico analyses and variant classifi-
cation according to both ACMG and NGSnPPGL study group 
guidelines were performed by a sole investigator (LBA) for 
consistency.
Curation by experts
After standardised ACMG and NGGnPPGL study group classifi-
cation, manual review of each variant was independently carried 
out by five experts (NB, JPB, MR, FS, AC), which involved 
choosing between two assigned classes when they were different, 
or applying a different classification based on personal expertise.
In case of discordance between expert classifications after 
the first round of reviewing, a second round of expert curation 
(NB, JPB, MR, PLD, RAT) was performed in order to achieve a 
consensus class for each variant.
RESULTS
Characterisation of the patient cohort
Clinical data were collected for 737 index cases carrying a SDHB 
variant (table 1).
Patients were affected by a single PPGL in 84.5% (618/731) 
of cases, multiple (2–7) PPGL in 14.1% (103/731), RCC only 
in 1.1% (8/731) and GIST only in 2 cases. The tumour loca-
tion was unknown for six patients. Among patients affected by 
a single PPGL with known location, 213 had a head and neck 
PGL (44.8%), 184 a thoracic, abdominal or pelvic PGL (38.7%) 
and 78 a PCC (16.4%). The precise tumour location was not 
specified for other patients (n=143). Metastatic disease was 
diagnosed in 133 patients, corresponding to 35.8% of cases 
with known benign/metastatic status. When family history was 
known, the disease was familial in 29.8% of cases (159/533). 
Twenty- three per cent of patients were affected during their 
fourth decade. The minimum age at diagnosis was 6 years, the 
mean age was 36 years and the maximum age was 83 years.
Variant characterisation
A total of 223 distinct variants have been collected from the 
737 entries (online supplemental table 2). Of these, 122 variants 
were found only once, 75 occurred 2–5 times, 12 were found 
6–10 times, 9 variants occurred between 11 and 20 times and 
5 variants were found 20 or more times. As regards the type 
of variant, 162 (73%) were nucleotide substitutions including 
missense (n=98, 44%), nonsense (n=21, 9%), splicesite (n=20, 
9%), mid- intronic (n=12, 5%), synonymous (n=6, 3%), 5' 
untranslated region (n=3, 1%) and initiation codon (n=2, 
1%) variants. Other variants consisted of 61 (27%) deletions 
or duplications including indels leading to a frameshift (n=38, 
17%), large deletions/duplications (n=14, 6%), in- frame dele-
tions (n=4, 2%) or indels affecting non- coding regions (n=3, 
1%) or splicesites (n=2, 1%) (figure 1). SDHB exonic variants 
are distributed along the entire coding sequence of the gene 
(figure 2). Relative to exon size, SDHB substitutions or indels 
are more frequent in exon 7 (36 variants for 123 bp), exon 6 (29 
variants for 102 bp) and exon 4 (36 variants for 137 bp). Exon 
8 is rarely involved, with only two substitutions within 78 bp.
Of the 223 distinct variants, 166 had been previously 
described (135 in SDHB- LOVD, 107 in ClinVar, 84 in dbSNP, 
49 in gnomAD and 14 in ESP). To our knowledge, 57 vari-
ants have not been previously reported in any database (online 
supplemental table 2).
Variant classification based on ACMG and NGSnPPGL 
recommendations
Each variant was classified according to criteria from both the 
ACMG and NGSnPPGL frameworks (figure 3). This step led to 
concordant classification of 161 variants, comprising 6 LBV, 61 
VUS, 70 LPV and 24 PV variants. Sixty- two variants showed 
Table 1 Clinical presentation of patients included in the study
Clinical data
All index cases 
with SDHB variant 
(n=737)





Single PPGL 618 (84.5%) 514 (84.3%)
Single headandneck 
PGL
213 (44.8%) 171 (44.5%)
Single TAP- PGL 184 (38.7%) 166 (43.2%)




Multiple PPGL 103 (14.1%) 89 (14.6%)
RCC only 8 (1.1%) 5 (0.8%)
GIST only 2 (0.3%) 2 (0.3%)





Metastatic disease 133 (35.8%) 122 (40%)
Benign disease 238 (64.2%) 183 (60%)
Metastatic status not specified 366 309
Familial/Sporadic 
presentation
Family history 159 (29.8%) 142 (33.1%)
No family history 374 (70.2%) 287 (66.9%)
Family history not specified 204 185
GIST, gastrointestinal stromal tumour; PCC, pheochromocytoma; PGL, paraganglioma; PPGL, 
paraganglioma/pheochromocytoma; RCC, renal cell carcinoma; TAP- PGL, thoracic, abdominal 
or pelvic PGL.
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discordant ratings based on ACMG and NGSnPPGL criteria, 
including 4 BV/LBV, 1 VUS/BV, 17 VUS/LBV, 23 LPV/VUS, 6 
VUS/PV and 11 LPV/PV.
Variant assessment by a panel of experts
After the first round of manual reviewing of all variants by the 
experts, the ACMG/NGSnPPGL classification, when concor-
dant, remained unchanged for 91/161 variants (5 LBV, 28 
VUS, 35 LPV and 23 PV). All experts agreed to convert nine 
originally LPV to PV including three gross deletions (deletion 
encompassing exons 1–7, exons 2–8 or the whole gene), two 
affecting splice junctions (c.423+1G>C and c.540G>C), 3 
missense (p.Gly208Glu, p.Arg230His and p.Cys253Tyr) and one 
nonsense (p.Arg90Ter) variant, due to cumulative evidence of 
pathogenicity and/or high recurrence in patients.
For variants that were originally discordant between the two 
classification systems (n=62), the first round of curation led 
to the unanimous assignment of 48 variants to a single class, 
including 2 BV, 12 LBV, 12 VUS, 8 LPV and 14 PV (figure 3).
Variant classification after the second round of curation
Following the first expert review, 75 variants remained without 
an unanimous classification, comprising 5 VUS or LBV, 5 VUS or 
PV, 36 VUS or LPV and 29 LPV or PV. These 75 variants were 
then submitted to a second round of expert review. Based on a 
careful review of additional data obtained during the reviewing 
process (new publications, SDHB immunohistochemistry results, 
description of new probands carrying the variant) and on their 
own expertise, the curators reached consensus on all variants.
After the final round of curation, the 223 distinct SDHB vari-
ants were classified as follows: 2 benign, 21 likely benign, 51 
VUS, 83 likely pathogenic and 66 pathogenic variants (figures 3 
and 4).
DISCUSSION
With extensive data collected from 737 SDHB- positive index 
cases, this study provides the first comprehensive overview of 
SDHB variants identified worldwide. The 223 distinct vari-
ants reported here were first classified according to a five- tier 
grouping using both the ACMG guidelines and the recommen-
dations specifically designed for PPGL susceptibility genes estab-
lished by the NGSnPPGL study group. All variants were then 
curated by a panel of international experts in the field based 
on two rounds of review. This multistep process resulted in a 
consensus classification for each variant. This expert- curated 
SDHB variant database is now freely available for the scientific 
community in the LOVD system (https://databaseslovdnl/shared/
genes/SDHB).12
The distribution of variant types in this study is in accor-
dance with prior reports.21 Regarding missense variants, 38% 
are located in either L(I)YR Fe- S transfer motifs or in the Fe- S 
cluster- ligating cysteines as previously reported (figure 2).22 The 
high rate of gross SDHB deletions or duplications, carried by 
12% of index cases (86/737) and including hotspots such as exon 
1 deletion (see below), is confirmed in this study and emphasises 
the importance of searching for large rearrangements using NGS 
or dedicated methods like MLPA.23 Most variants were reported 
only once (55%, n=123) but 14 were recorded >10 times 
including the deletion of exon 1 (52 reports), the c.72+1A>G 
and c.137G>A variants (39 reports each) and the c.166_170del 
and the c.689G>A variants (21 reports each), thereby revealing 
several likely mutational hot spots or founder mutations.21 24 25 
Figure 1 Distribution of SDHB variants according to the type of 
alteration RGT: rearrangement. UTR, untranslated region.
Figure 2 Diagram of the coding SDHB variants along the amino acid sequence L(I)YR motifs are shown in blue. The cysteine residues ligating the [Fe2- S2], 
the [Fe4- S4] and the [Fe3- S4] are shown in orange, red and purple, respectively. Diagram is displayed as lollipop symbols designed using the Mutation Mapper 
tool of the cBioPortal website. The Y axis represents the number of occurrences of variant in one residue.
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The founder Dutch mutations c.423+1G>A and SDHB exon 3 
deletion were reported 18 and 9 times, respectively.26 Twenty- 
five per cent of the variants reported here had not been previ-
ously described.
Until recently, laboratories largely used their own methods to 
assess variant pathogenicity, leading to discrepancies between 
interpretations.27 Guidelines for variant interpretation were 
established in 2015 by the ACMG, encouraging harmonisation 
in variant classification.14 These guidelines have now been widely 
adopted by laboratories internationally. However, some ACMG 
criteria may be applied or weighted differently depending on 
the laboratory.28 Moreover, as ACMG guidelines aim at being 
applicable to all genes that cause Mendelian disorders, they 
cannot take into account the specificities of one particular gene 
or disease.14 This consideration has prompted to the develop-
ment of many national or international consortia of experts 
on particular genes or diseases, and has led to the develop-
ment of dedicated recommendations for variant interpretation. 
Regarding cancer predisposing genes, these international efforts 
have mainly been initiated for common cancers such as breast 
cancer or Lynch syndrome29–31 or ‘iconic’ tumour suppressor 
genes such as TP53.32 Regarding PPGL predisposition, the inter-
national NGSnPPGL study group recently published guidelines 
designed specifically for PPGL susceptibility genes.2 One of the 
main goals of these guidelines is to minimise the number of VUS 
because inconclusive report on these variants may cause confu-
sion and anxiety for both patients and physicians. Moreover, this 
situation can introduce ambiguities in patient care because no 
Figure 4 Distribution of SDHB variant types according to the 5- tier classification. VUS, variant of unknown significance; UTR, untranslated region.
Figure 3 Strategy for variant classification. ACMG, American College of Medical Genetics and Genomics; BV, benign variant; LBV, likely benign variant; LPV, 
likely pathogenic variant; PV, pathogenic variant; VUS, variant of unknown significance.
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established medical management for VUS carriers exists. Finally, 
a VUS cannot be used in predictive gene testing in relatives. 
Resolving the pathogenicity of a VUS is therefore essential. In 
the context of predisposition to PPGL, patients carrying a germ-
line likely pathogenic or pathogenic variant in a PPGL suscepti-
bility gene should undergo lifelong follow- up including, in the 
case of SDHB, careful monitoring for risk of metastases, GIST 
or RCC development.33 Moreover, as SDHB- related PPGL can 
occur early in childhood, predictive genetic testing and subse-
quent first screening by imaging, together with long- life surveil-
lance, should be started at age 5–6 years in carriers of likely 
pathogenic/pathogenic SDHB variants.34
The ACMG and NGSnPPGL criteria were applied to assess 
all variants collected. The class assigned by both methods was 
the same in the majority of cases (n=161, 72%). In case of 
discordance (n=62, 28%), the ACMG classification generally 
assigned VUS (n=45) while the NGSnPPGL framework only 
assigned two VUS. These results suggest that the NGSnPPGL 
disease- specific recommendations are more pertinent for PPGL 
genetic counselling than standard ACMG criteria. In total, one 
or both methods ended in a VUS status for almost half of vari-
ants (n=108, 48%). After curation by experts, most were reas-
sessed and the number of VUS decreased dramatically to 51 in 
total (22%). This result highlights both the challenge and the 
important impact of SDHB variant interpretation performed by 
experts.
In total, 77% (n=172) of variants described in the present 
study could be classified either as benign/likely benign (10%, 
n=23) or as likely pathogenic/pathogenic (67%, n=149). The 
relatively low rate of non- pathogenic variants is explained 
because frequent or well- known polymorphisms were not 
collected. Results of additional/functional data were helpful 
for classification of 94 (42%) variants. Depending on variants, 
we compiled results obtained from mutated tumour tissue and 
comprising SDHB±SDHA immunohistochemistry (n=75), LOH 
detection (n=26), transcriptomic clustering (n=24), cDNA anal-
ysis (n=15), western blot analysis (n=7) and measurement of 
SDH enzymatic activity (n=6) (online supplemental table 2 and 
figure 1).
Considering the whole cohort of 737 affected patients, 614 of 
them (83.3%) carry a likely pathogenic or a pathogenic variant. 
The comparison of the clinical data available for both popula-
tions (table 1) revealed no significant difference, confirming that 
the patient’s phenotype does not allow to classify a variant as 
pathogenic or not. Noticeably, the occurrence of GIST or RCC 
is not associated with a specific genotype as all variants identified 
in patients with GIST or RCC were also found in patients with 
PPGL only.
Finally, class 3 includes 51 variants with limited data or/and 
no relevant or contradictory evidence for pathogenicity such as 
immunohistochemistry results, mostly because no tumour tissue 
was available or because discordant results were obtained. As 
expected, VUS exclusively comprise non- truncating variants, 
including 37/98 missense, 10/18 non- coding variants and 3/4 
in- frame indels. Moreover, we were unable to determine the 
pathogenicity of whole gene SDHB duplication.
Finally, the consensus classification (as well as pertinent infor-
mation and the following comment: ‘variant classified by experts 
from the NGSnPPGL study group (ENS@T/PRESSOR)’) for the 
223 collected variants has been deposited in the LOVD- SDHB 
database in order to share a free, valuable and updated resource 
with the community. International efforts should continue, and 
laboratories/centres are encouraged to systematically submit 
and review data for new variants and for already reported VUS, 
because reassessment may result in changes in variant classifica-
tion as new evidence becomes available.
In summary, we collected SDHB variants worldwide and gath-
ered an international group of curators committed to working 
together to expertly classify these variants. These experts under-
took a joint effort to collect, share, integrate and then discuss 
multiple strands of evidence pertaining to SDHB genetic vari-
ants, with the objective of determining the clinical relevance of a 
variant to ultimately improve the clinical utility of genetic testing 
in patients and their relatives.
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